Published in Antimicrob Agents Chemother on February 01, 2005
Functional analysis of DNA gyrase mutant enzymes carrying mutations at position 88 in the A subunit found in clinical strains of Mycobacterium tuberculosis resistant to fluoroquinolones. Antimicrob Agents Chemother (2006) 1.42
Effects of treatment with antimicrobial agents on the human colonic microflora. Ther Clin Risk Manag (2008) 1.13
Comparative transcription analysis and toxin production of two fluoroquinolone-resistant mutants of Clostridium perfringens. BMC Microbiol (2013) 0.81
Enhanced production of phospholipase C and perfringolysin O (alpha and theta toxins) in a gatifloxacin-resistant strain of Clostridium perfringens. Antimicrob Agents Chemother (2007) 0.80
Global Phenotypic Characterization of Effects of Fluoroquinolone Resistance Selection on the Metabolic Activities and Drug Susceptibilities of Clostridium perfringens Strains. Int J Microbiol (2014) 0.77
Effect of Trehalose and Trehalose Transport on the Tolerance of Clostridium perfringens to Environmental Stress in a Wild Type Strain and Its Fluoroquinolone-Resistant Mutant. Int J Microbiol (2016) 0.75
DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev (1997) 9.69
Mechanism of plasmid-mediated quinolone resistance. Proc Natl Acad Sci U S A (2002) 7.76
Quinolone resistance-determining region in the DNA gyrase gyrB gene of Escherichia coli. Antimicrob Agents Chemother (1991) 6.19
Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolones. Antimicrob Agents Chemother (1997) 3.83
A single point mutation in the DNA gyrase A protein greatly reduces binding of fluoroquinolones to the gyrase-DNA complex. Antimicrob Agents Chemother (1993) 3.43
Mutation rate and evolution of fluoroquinolone resistance in Escherichia coli isolates from patients with urinary tract infections. Antimicrob Agents Chemother (2003) 3.00
DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance. Proc Natl Acad Sci U S A (1997) 2.99
Fluoroquinolone action against mycobacteria: effects of C-8 substituents on growth, survival, and resistance. Antimicrob Agents Chemother (1998) 2.35
Selection of antibiotic-resistant bacterial mutants: allelic diversity among fluoroquinolone-resistant mutations. J Infect Dis (2000) 2.35
Gatifloxacin activity against quinolone-resistant gyrase: allele-specific enhancement of bacteriostatic and bactericidal activities by the C-8-methoxy group. Antimicrob Agents Chemother (1999) 2.16
Comparative experiments to examine the effects of heating on vegetative cells and spores of Clostridium perfringens isolates carrying plasmid genes versus chromosomal enterotoxin genes. Appl Environ Microbiol (2000) 2.12
Ciprofloxacin-resistant Haemophilus influenzae strains possess mutations in analogous positions of GyrA and ParC. Antimicrob Agents Chemother (1996) 2.07
Fluoroquinolones: action and resistance. Curr Top Med Chem (2003) 2.04
Mechanism of fluoroquinolone action. Curr Opin Microbiol (1999) 1.98
In vitro antibacterial spectrum of a new broad-spectrum 8-methoxy fluoroquinolone, gatifloxacin. J Antimicrob Chemother (2000) 1.88
Killing of Staphylococcus aureus by C-8-methoxy fluoroquinolones. Antimicrob Agents Chemother (1998) 1.86
Novel gyrA point mutation in a strain of Escherichia coli resistant to fluoroquinolones but not to nalidixic acid. Antimicrob Agents Chemother (1993) 1.73
Critical appraisal of E test for the detection of fluoroquinolone resistance. J Antimicrob Chemother (1996) 1.60
A MATE family multidrug efflux transporter pumps out fluoroquinolones in Bacteroides thetaiotaomicron. Antimicrob Agents Chemother (2001) 1.55
Fulminant and fatal gas gangrene of the stomach in a healthy live liver donor. Liver Transpl (2004) 1.44
Mutation in the DNA gyrase A Gene of Escherichia coli that expands the quinolone resistance-determining region. Antimicrob Agents Chemother (2001) 1.40
Prevalence of antibiotic resistance in anaerobic bacteria: worrisome developments. Clin Infect Dis (2004) 1.38
gyrA and gyrB mutations are implicated in cross-resistance to Ciprofloxacin and moxifloxacin in Clostridium difficile. Antimicrob Agents Chemother (2002) 1.34
Gatifloxacin. Drugs (1999) 1.22
Comparative activity of moxifloxacin in vitro against obligately anaerobic bacteria. Eur J Clin Microbiol Infect Dis (2000) 1.14
Resistance to moxifloxacin in toxigenic Clostridium difficile isolates is associated with mutations in gyrA. Antimicrob Agents Chemother (2001) 1.14
In vitro susceptibility of anaerobes to quinolones in the United States. Clin Infect Dis (1996) 1.13
Mechanism of quinolone action. A drug-induced structural perturbation of the DNA precedes strand cleavage by topoisomerase IV. J Biol Chem (1997) 1.06
Analysis of the mutations involved in fluoroquinolone resistance of in vivo and in vitro mutants of Escherichia coli. Microb Drug Resist (1998) 1.00
gyrA mutations associated with quinolone resistance in Bacteroides fragilis group strains. Antimicrob Agents Chemother (2001) 1.00
In vitro activity of new quinolones against Clostridium difficile. J Antimicrob Chemother (2001) 0.95
Plasmid-mediated complementation of gyrA and gyrB in fluoroquinolone-resistant Bacteroides fragilis. J Antimicrob Chemother (2003) 0.87
Importance of the fourth alpha-helix within the CAP homology domain of type II topoisomerase for DNA cleavage site recognition and quinolone action. Antimicrob Agents Chemother (2002) 0.86
Isolation of nitrofurantoin-resistant mutants of nitroreductase-producing Clostridium sp. strains from the human intestinal tract. Antimicrob Agents Chemother (1998) 0.83
Molecular characterization of resistance to extended-spectrum cephalosporins in clinical Escherichia coli isolates from companion animals in the United States. Antimicrob Agents Chemother (2011) 1.22
Mutations in SOHLH1 gene associate with nonobstructive azoospermia. Hum Mutat (2010) 0.98
Quorum sensing: a primer for food microbiologists. J Food Prot (2004) 0.95
Variations in metabolism of the soy isoflavonoid daidzein by human intestinal microfloras from different individuals. Arch Microbiol (2003) 0.92
Contribution of IL23R but not ATG16L1 to Crohn's disease susceptibility in Koreans. Inflamm Bowel Dis (2009) 0.91
Isolation of bacterial strains from bovine fecal microflora capable of degradation of ceftiofur. Vet Microbiol (2009) 0.87
Evidence for active drug efflux in fluoroquinolone resistance in Clostridium hathewayi. Chemotherapy (2005) 0.83
Comparative transcription analysis and toxin production of two fluoroquinolone-resistant mutants of Clostridium perfringens. BMC Microbiol (2013) 0.81
Diversity of moxifloxacin resistance during a nosocomial outbreak of a predominantly ribotype ARU 027 Clostridium difficile diarrhea. Anaerobe (2009) 0.81
Comparison of the metabolic activities of four wild-type Clostridium perfringens strains with their gatifloxacin-selected resistant mutants. Arch Microbiol (2009) 0.80
Enhanced production of phospholipase C and perfringolysin O (alpha and theta toxins) in a gatifloxacin-resistant strain of Clostridium perfringens. Antimicrob Agents Chemother (2007) 0.80
The validity and reliability of a Computerized Dementia Screening Test developed in Korea. J Neurol Sci (2002) 0.80
The oocyte-specific transcription factor, Nobox, regulates the expression of Pad6, a peptidylarginine deiminase in the oocyte. FEBS Lett (2010) 0.79
Characterization of an ATP-binding cassette from Clostridium perfringens with homology to an ABC transporter from Clostridium hathewayi. Anaerobe (2009) 0.78
Metabolism of daidzein by intestinal bacteria from rhesus monkeys (Macaca mulatta). Comp Med (2004) 0.78
Detection and characterization of an ABC transporter in Clostridium hathewayi. Arch Microbiol (2008) 0.77
Substitutions of amino acids in alpha-helix-4 of gyrase A confer fluoroquinolone resistance on Clostridium perfringens. Arch Microbiol (2006) 0.77
RASD1 Knockdown Results in Failure of Oocyte Maturation. Cell Physiol Biochem (2016) 0.75
Radiation resistance of virulence plasmid-containing and plasmid-less Yersinia enterocolitica. J Food Prot (2002) 0.75
Effects of gyrase mutation on the growth kinetics of ciprofloxacin-resistant strains of Clostridium perfringens. Anaerobe (2005) 0.75